Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy S Herbst

Showing results (1-10 of 375) with videos related to

Pageof 38
Sort By:
International Journal of Radiation Oncology, Biology, Physics|May 15, 2004
Review of epidermal growth factor receptor biologyRoy S Herbst
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
EGFR inhibition in NSCLC: the emerging role of cetuximabRoy S Herbst
Oncology (Williston Park, N.Y.)|October 12, 2002
Targeted therapy in non-small-cell lung cancerRoy S Herbst
Expert Opinion on Investigational Drugs|May 31, 2002
ZD1839: targeting the epidermal growth factor receptor in cancer therapyRoy S Herbst
Seminars in Oncology|July 4, 2003
Erlotinib (Tarceva): an update on the clinical trial programRoy S Herbst
Clinical Lung Cancer|May 27, 2008
Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men?Roy S Herbst
Clinical Lung Cancer|January 24, 2007
Toxicities of antiangiogenic therapy in non-small-cell lung cancerRoy S Herbst
Clinical Lung Cancer|September 3, 2011
Current and future strategies for antiangiogenic agents in non-small-cell lung cancerRoy S Herbst
Clinical Advances in Hematology & Oncology : H&O|February 25, 2012
Highlights in NSCLC From the IASLC (International Association for the Study of Lung Cancer) 14th World Conference on Lung CancerRoy S Herbst
The New England Journal of Medicine|December 30, 2025
Navigating the Evolving Landscape of <i>EGFR</i>-Mutated NSCLCRoy S Herbst
Pageof 38

Showing results (1-10 of 375) with videos related to

Sort By:
Pageof 38
International Journal of Radiation Oncology, Biology, Physics|May 15, 2004
Review of epidermal growth factor receptor biologyRoy S Herbst
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
EGFR inhibition in NSCLC: the emerging role of cetuximabRoy S Herbst
Oncology (Williston Park, N.Y.)|October 12, 2002
Targeted therapy in non-small-cell lung cancerRoy S Herbst
Expert Opinion on Investigational Drugs|May 31, 2002
ZD1839: targeting the epidermal growth factor receptor in cancer therapyRoy S Herbst
Seminars in Oncology|July 4, 2003
Erlotinib (Tarceva): an update on the clinical trial programRoy S Herbst
Clinical Lung Cancer|May 27, 2008
Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men?Roy S Herbst
Clinical Lung Cancer|January 24, 2007
Toxicities of antiangiogenic therapy in non-small-cell lung cancerRoy S Herbst
Clinical Lung Cancer|September 3, 2011
Current and future strategies for antiangiogenic agents in non-small-cell lung cancerRoy S Herbst
Clinical Advances in Hematology & Oncology : H&O|February 25, 2012
Highlights in NSCLC From the IASLC (International Association for the Study of Lung Cancer) 14th World Conference on Lung CancerRoy S Herbst
The New England Journal of Medicine|December 30, 2025
Navigating the Evolving Landscape of <i>EGFR</i>-Mutated NSCLCRoy S Herbst
Pageof 38